Recently, the China Venture Research Institute released its "2022 China Venture Award," in which Xiamen Industrial Investment Fund was selected as one of the "Top 30 Best Limited Partners in China for 2022." Additionally, Cellprobio, a medical device company invested by Xiamen Venture Independently Managed Fund, was included in the "Top 10 Investment Cases in the Medical Devices Sector of China's Medical and Health Services Industry." As a local guidance fund brand, Xiamen Industrial Investment Fund and its entrusted management institution, Xiamen Venture, have been listed in the "China Venture Award" for eight consecutive years. Since its establishment in 2011, Xiamen Industrial Investment Fund has now exceeded a scale of 100 billion yuan. In recent years, the fund has been actively expanding its investment portfolio in line with Xiamen's "4+4+6" modern industrial system. It has invested in over 300 companies in Xiamen, all within the targeted development areas of the city's industries.
